https://www.selleckchem.com/products/frax597.html
72 (0.52-0.99)]. Clopidogrel ever use was associated with a higher breast cancer risk [HR, 1.30 (1.02-1.68)], restricted to estrogen receptor negative (ER ) tumors [HR = 1.14 (0.83-1.57), HR = 3.07 (1.64-5.76), = 0.01]. Low-dose aspirin was associated with a lower breast cancer risk only after several years of use, while ever use of clopidogrel was associated with a higher ER breast cancer risk. Antiplatelet drugs are not good pharmacologic candidates for breast cancer prevention. Antiplatelet drugs are not good pharmacologic candidates